Navigation Links
US Dermatophytic Onychomycosis Market Discussed by GlobalData in Topical Report Now Available at MarketPublishers.com
Date:7/17/2013

London, UK (PRWEB) July 17, 2013

Dermatophytic onychomycosis (DO) is one of the most widespread fungal nail infections. It is not considered to be a life-threatening disease, but it can cause considerable pain and discomfort. At present, DO therapies consist of generics which are quite effective but are not as safe as their brand-name counterparts.

New topical DO therapies are predicted to be introduced in the offing, and they are likely to scale up the total drug treatment rates in the US owing to increasing physicians’ awareness of safer and more effective treatment options. Meanwhile, given their advantages such as a shorter duration of treatment, generic therapies represent a challenge to the development of the innovative therapies.

Topical research report “PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022” elaborated by GlobalData has been recently published by Market Publishers Ltd.

Report Details:

Title: PharmaPoint: Dermatophytic Onychomycosis (DO) - US Drug Forecast and Market Analysis to 2022
Published: June, 2013
Pages: 146
Price:    US$ 4,995.00
http://marketpublishers.com/report/pharmaceuticals/drugs/dermatophytic-onychomycosis-do-us-drug-forecast-n-market-analysis-to-2022.html

The report provides in-depth insights into the US DO market. It uncovers vital general information on DO including its epidemiology, key symptoms and disease treatment; and also discloses historical and present data on the DO market revenues, annual therapy costs, treatment usage patterns, etc. The study contains a comprehensive pipeline analysis, evaluates the competitive environment, and presents details on the top companies operating in the market. The report examines major market drivers and restraints, outlines the market opportunities and challenges, characterizes prevailing development trends, and moreover, sheds light on the possible path of the market development through 2022.

Report Scope:

  •     Comprehensive overview of DO (epidemiology, general symptoms, disease treatment recommendations, etc.).
  •     All-round analysis of the US DO market.
  •     Historical and present data on the market performance.
  •     Description of the competitive scenario.
  •     Vital information on the major market opportunities.
  •     Clinical pipeline assessment.
  •     Profiles of the leading market players.
  •     Discussion of the important industry issues.
  •     Examination of the factors driving and restraining the market development.
  •     Detailed future market forecast up to 2022.

More research studies by the publisher can be found at GlobalData page.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10937702.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
2. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
3. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
4. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
5. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
6. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
7. ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market
8. GeneLink Marketing Efforts Poised to Show Results
9. Animal Biotechnology - Technologies, Markets and Companies
10. Gene Therapy - Technologies, Markets and Companies
11. Biomarkers - Technologies, Markets and Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... SEATTLE , March 23, 2017 ... translational development of novel therapies in immuno-oncology, today ... to lead" small molecule compounds that activate interferon ... (RLR) pathways and demonstrate immune-mediated tumor regression in ... in the study who demonstrated complete tumor regression ...
(Date:3/23/2017)... According to a report by Transparency Market ... due to the presence of a large pool of participants; however, ... , and Sigma-Aldrich, compete with each other in this market. With ... than 76% of this market in 2016.  ... As of now, a large number of ...
(Date:3/23/2017)... March 23, 2017 In today,s ... equities in the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: ... (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market ... free report at: ...
(Date:3/22/2017)... -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a major ... and GSK to generate genetic sequence data from the 500,000 ... enable researchers to gain valuable insights to support advances in ... serious and life threatening diseases. ... Genetic evidence has revolutionized scientific ...
Breaking Biology Technology:
(Date:3/13/2017)... 2017 Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other or ... individuals. (PRNewsFoto/Dermalog Identification Systems) ... "Face Matching" is the fastest software for biometric Face Matching on the market. ...
(Date:3/6/2017)... , March 6, 2017 ... sales technology, today announced Predictive Sales Coach TM ... infusing actionable sales intelligence into Salesforce. This unique ... enable their sales organizations with deep knowledge of ... allow for intelligent engagement. Predictive Sales Coach extends ...
(Date:3/1/2017)... BEDFORD, Mass. , March 1, 2017  Aware, ... and services, announced that Richard P. Moberg ... Officer and co-President and Chief Financial Officer and Treasurer ... will continue to serve as a member of the ... T. Russell , Aware,s co-Chief Executive Officer and co-President, ...
Breaking Biology News(10 mins):